Vijaya Diagnostic Centre Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
VIJAYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.4 pts more than Nifty Smallcap 250 and 4.1 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vijaya Diagnostic Centre reported strong full-year results with standalone revenue from operations growing 20.7% to Rs. 76,543 Lakhs (FY25: Rs. 63,400 Lakhs). Profit after tax rose 31.2% to Rs. 17,831 Lakhs (FY25: Rs. 13,593 Lakhs), driven by higher diagnostic service volumes and operational efficiencies. EBITDA margin expanded to an estimated ~41.4% from ~39.1% in the prior year. The company completed the amalgamation of subsidiary Medinova Diagnostic Services Limited effective April 1, 2024, with prior-year comparatives restated accordingly. The Board recommended a dividend of Rs. 2 per share (200%). Statutory auditors issued an unmodified (clean) opinion. Pending new Indian labour codes required recognition of additional gratuity and leave liability of Rs. 78.82 Lakhs, disclosed as an emphasis of matter.
Revenue growth above 20% and PAT growth above 31% demonstrate strong operational performance and margin expansion, which should be positive for the stock. The clean audit opinion and completed Medinova amalgamation remove key investor concerns.